ArticleJournal of pharmaceutical policy and practice2026
The prevalence and predictor factors of urinary tract infection in type 2 diabetes mellitus patients receiving SGLT2 inhibitors in Qatar: A retrospective cohort study.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods: A retrospective cohort study was conducted at two hospitals to evaluate UTI prevalence and predictors in elderly T2DM patients treated with SGLT2 inhibitors. Data from electronic health records over one year were analysed. Patients aged 60 + with a UTI diagnosis within 90 days of starting SGLT2 inhibitors were included. The primary outcome was UTI prevalence; secondary outcomes included factors like age, gender, comorbidities, HbA1c levels, and kidney function. Results: In a cohort of 1,024 elderly T2DM patients, 49% experienced UTIs. Significant predictors included gender, nationality, and age. Females had a higher UTI prevalence (68% vs. 32%, Conclusion: The study identified varying risks of urinary tract infections (UTIs) among users of SGLT2 inhibitors, influenced by factors like gender, age, and existing health conditions. This underscores the need for cautious prescribing of SGLT2 inhibitors, emphasising personalised risk assessment and careful evaluation of benefits versus risks. Future research should focus on refining UTI risk prediction and developing targeted interventions for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.